Invicro Launches AmyloidIQ to Advance Clinical Imaging Trials in Alzheimer’s Disease

09:52 EDT 19 Mar 2018 | Businesswire

This article has expired, however you can still download the PDF.
Invicro LLC, a Konica Minolta company and a leading provider of imaging services and software for research and drug development, recently announced the launch of AmyloidIQ, a new and advanced algorithm that quantifies Amyloid sc...

Other Sources for this Article

Invicro LLC
Amanda Harrell
VP, Global Marketing


More From BioPortfolio on "Invicro Launches AmyloidIQ to Advance Clinical Imaging Trials in Alzheimer’s Disease"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...